Aurobindo Pharma Future Growth
Future criteria checks 1/6
Aurobindo Pharma is forecast to grow earnings and revenue by 12.6% and 7.7% per annum respectively. EPS is expected to grow by 12.4% per annum. Return on equity is forecast to be 12.7% in 3 years.
Key information
12.6%
Earnings growth rate
12.4%
EPS growth rate
Pharmaceuticals earnings growth | 18.5% |
Revenue growth rate | 7.7% |
Future return on equity | 12.7% |
Analyst coverage | Good |
Last updated | 17 Oct 2024 |
Recent future growth updates
Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422
Aug 13Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Recent updates
Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Sep 10This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422
Aug 13Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
May 22Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Apr 14Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 363,933 | 48,421 | 44,762 | N/A | 18 |
3/31/2026 | 347,837 | 46,788 | 34,814 | N/A | 27 |
3/31/2025 | 315,765 | 39,164 | 27,528 | N/A | 27 |
6/30/2024 | 297,184 | 35,214 | N/A | N/A | N/A |
3/31/2024 | 290,019 | 31,730 | -11,270 | 24,345 | N/A |
12/31/2023 | 278,947 | 27,705 | N/A | N/A | N/A |
9/30/2023 | 269,500 | 23,254 | -16,080 | 19,946 | N/A |
6/30/2023 | 254,700 | 19,777 | N/A | N/A | N/A |
3/31/2023 | 248,554 | 19,275 | -3,336 | 23,868 | N/A |
12/31/2022 | 241,918 | 19,977 | N/A | N/A | N/A |
9/30/2022 | 237,869 | 21,112 | 28,497 | 52,208 | N/A |
6/30/2022 | 239,894 | 23,987 | N/A | N/A | N/A |
3/31/2022 | 234,555 | 26,482 | 23,118 | 50,165 | N/A |
12/31/2021 | 236,476 | 28,676 | N/A | N/A | N/A |
9/30/2021 | 240,103 | 52,109 | 1,278 | 28,769 | N/A |
6/30/2021 | 245,518 | 53,217 | N/A | N/A | N/A |
3/31/2021 | 247,746 | 53,348 | 14,552 | 33,291 | N/A |
12/31/2020 | 249,316 | 53,831 | N/A | N/A | N/A |
9/30/2020 | 244,617 | 31,421 | 29,266 | 42,542 | N/A |
6/30/2020 | 235,787 | 29,757 | N/A | N/A | N/A |
3/31/2020 | 230,985 | 28,451 | 29,502 | 43,813 | N/A |
12/31/2019 | 222,323 | 25,666 | N/A | N/A | N/A |
9/30/2019 | 216,070 | 25,733 | N/A | N/A | N/A |
6/30/2019 | 207,579 | 25,449 | N/A | N/A | N/A |
3/31/2019 | 195,636 | 23,647 | 919 | 16,510 | N/A |
12/31/2018 | 183,834 | 23,078 | N/A | N/A | N/A |
9/30/2018 | 174,246 | 21,906 | N/A | N/A | N/A |
6/30/2018 | 171,091 | 23,603 | N/A | N/A | N/A |
3/31/2018 | 164,630 | 24,232 | N/A | 19,545 | N/A |
12/31/2017 | 159,381 | 24,271 | N/A | N/A | N/A |
9/30/2017 | 154,903 | 24,107 | N/A | N/A | N/A |
6/30/2017 | 148,279 | 22,352 | N/A | N/A | N/A |
3/31/2017 | 149,334 | 23,017 | N/A | 32,786 | N/A |
12/31/2016 | 151,565 | 22,809 | N/A | N/A | N/A |
9/30/2016 | 147,559 | 22,466 | N/A | N/A | N/A |
6/30/2016 | 143,446 | 20,945 | N/A | N/A | N/A |
3/31/2016 | 138,162 | 20,251 | N/A | 14,198 | N/A |
12/31/2015 | 133,249 | 18,230 | N/A | N/A | N/A |
9/30/2015 | 129,956 | 16,724 | N/A | N/A | N/A |
6/30/2015 | 125,433 | 15,928 | N/A | N/A | N/A |
3/31/2015 | 121,340 | 15,758 | N/A | 12,368 | N/A |
12/31/2014 | 112,825 | 16,738 | N/A | N/A | N/A |
9/30/2014 | 102,756 | 17,069 | N/A | N/A | N/A |
6/30/2014 | 93,109 | 15,697 | N/A | N/A | N/A |
3/31/2014 | 81,002 | 11,729 | N/A | 6,463 | N/A |
12/31/2013 | 73,736 | 7,797 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AUROPHARMA's forecast earnings growth (12.6% per year) is above the savings rate (6.7%).
Earnings vs Market: AUROPHARMA's earnings (12.6% per year) are forecast to grow slower than the Indian market (17.4% per year).
High Growth Earnings: AUROPHARMA's earnings are forecast to grow, but not significantly.
Revenue vs Market: AUROPHARMA's revenue (7.7% per year) is forecast to grow slower than the Indian market (10.1% per year).
High Growth Revenue: AUROPHARMA's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AUROPHARMA's Return on Equity is forecast to be low in 3 years time (12.7%).